CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase 2 Study of the PARP Inhibitor Olaparib (AZD2281) in IDH1 and IDH2 Mutant Advanced Solid Tumors

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT03212274
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-25T22:28:24.013299+00:00
Published At: 2026-02-19T00:00:00+00:00
Record Updated At: 2026-02-19
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Advanced Malignant Solid Neoplasm", "Glioblastoma", "Recurrent Cholangiocarcinoma", "Recurrent Glioma", "Recurrent Malignant Solid Neoplasm", "WHO Grade 2 Glioma", "WHO Grade 3 Glioma"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2026-02-19"
protocolSection.identificationModule.nctId: "NCT03212274"
protocolSection.identificationModule.officialTitle: "A Phase 2 Study of the PARP Inhibitor Olaparib (AZD2281) in IDH1 and IDH2 Mutant Advanced Solid Tumors"
protocolSection.statusModule.overallStatus: "ACTIVE_NOT_RECRUITING"
protocolSection.designModule.phases: ["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.